Zusman, Oren Altunin, Sergey Koppel, Fidi Dishon Benattar, Yael Gedik, Habip and Paul, Mical 2017. Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, Vol. 72, Issue. 1, p. 29.
Averbuch, Diana and Engelhard, Dan 2016. Transplant Infections.
Choi, Ik Sung Lee, Yu Ji Wi, Yu Mi Kwan, Byung Soo Jung, Kae Hwa Hong, Woong Pyo and Kim, June Myong 2016. Predictors of mortality in patients with extensively drug-resistant Acinetobacter baumannii pneumonia receiving colistin therapy. International Journal of Antimicrobial Agents, Vol. 48, Issue. 2, p. 175.
Clark, Nina M. Zhanel, George G. and Lynch, Joseph P. 2016. Emergence of antimicrobial resistance among Acinetobacter species. Current Opinion in Critical Care, Vol. 22, Issue. 5, p. 491.
Garnacho-Montero, José Gutiérrez-Pizarraya, Antonio Díaz-Martín, Ana Cisneros-Herreros, José Miguel Cano, María Eugenia Gato, Eva Ruiz de Alegría, Carlos Fernández-Cuenca, Felipe Vila, Jordi Martínez-Martínez, Luis Tomás-Carmona, M. del Mar Pascual, Álvaro Bou, Germán Pachón-Diaz, Jerónimo and Rodríguez-Baño, Jesús 2016. Acinetobacter baumannii in critically ill patients: Molecular epidemiology, clinical features and predictors of mortality. Enfermedades Infecciosas y Microbiología Clínica, Vol. 34, Issue. 9, p. 551.
Gul, Serdar Kuscu, Ferit Aydemir, Hande Ozturk, Dogan Baris Deveci, Ozcan Duygu, Fazilet Kacmaz, Birgul Yaman, Ferda and Aslan, Emel 2016. Risk Factors for Colistin-Associated Acute Kidney Injury: A Multicenter Study from Turkey. Japanese Journal of Infectious Diseases, Vol. 69, Issue. 2, p. 109.
Hudcova, Jana Craven, Kathleen A. and Craven, Donald E. 2016. Surgical Intensive Care Medicine.
Idelevich, Evgeny A. Lanckohr, Christian Horn, Dagmar Wieler, Lothar H. Becker, Karsten and Köck, Robin 2016. Antibiotika-resistente Erreger in Deutschland. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, Vol. 59, Issue. 1, p. 113.
Kalil, Andre C. Metersky, Mark L. Klompas, Michael Muscedere, John Sweeney, Daniel A. Palmer, Lucy B. Napolitano, Lena M. O'Grady, Naomi P. Bartlett, John G. Carratalà, Jordi El Solh, Ali A. Ewig, Santiago Fey, Paul D. File, Thomas M. Restrepo, Marcos I. Roberts, Jason A. Waterer, Grant W. Cruse, Peggy Knight, Shandra L. and Brozek, Jan L. 2016. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical Infectious Diseases, Vol. 63, Issue. 5, p. e61.
Kaye, Keith S. Pogue, Jason M. Tran, Thien B. Nation, Roger L. and Li, Jian 2016. Agents of Last Resort. Infectious Disease Clinics of North America, Vol. 30, Issue. 2, p. 391.
Özvatan, Tülay Akalın, Halis Sınırtaş, Melda Ocakoğlu, Gökhan Yılmaz, Emel Heper, Yasemin Kelebek, Nermin İşçimen, Remzi and Kahveci, Ferda 2016. Nosocomial Acinetobacter pneumonia: Treatment and prognostic factors in 356 cases. Respirology, Vol. 21, Issue. 2, p. 363.
Parchem, N. L. Bauer, K. A. Cook, C. H. Mangino, J. E. Jones, C. D. Porter, K. and Murphy, C. V. 2016. Colistin combination therapy improves microbiologic cure in critically ill patients with multi-drug resistant gram-negative pneumonia. European Journal of Clinical Microbiology & Infectious Diseases, Vol. 35, Issue. 9, p. 1433.
Rai, M. Kon, K. Gade, A. Ingle, A. Nagaonkar, D. Paralikar, P. and da Silva, S.S. 2016. Antibiotic Resistance.
Thatrimontrichai, Anucha Techato, Chirabat Dissaneevate, Supaporn Janjindamai, Waricha Maneenil, Gunlawadee Kritsaneepaiboon, Supika and Tanaanantarak, Pattama 2016. Risk factors and outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia in the neonate: A case-case-control study. Journal of Infection and Chemotherapy, Vol. 22, Issue. 7, p. 444.
Tsioutis, Constantinos Kritsotakis, Evangelos I. Karageorgos, Spyridon A. Stratakou, Soultana Psarologakis, Charalambos Kokkini, Sofia and Gikas, Achilleas 2016. Clinical epidemiology, treatment and prognostic factors of extensively drug-resistant Acinetobacter baumannii ventilator-associated pneumonia in critically ill patients. International Journal of Antimicrobial Agents, Vol. 48, Issue. 5, p. 492.
Bailey, Kristina L. and Kalil, Andre C. 2015. Ventilator-Associated Pneumonia (VAP) with Multidrug-Resistant (MDR) Pathogens: Optimal Treatment?. Current Infectious Disease Reports, Vol. 17, Issue. 8,
Bergen, Phillip J. Bulman, Zackery P. Landersdorfer, Cornelia B. Smith, Nicholas Lenhard, Justin R. Bulitta, Jürgen B. Nation, Roger L. Li, Jian and Tsuji, Brian T. 2015. Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria. Infectious Diseases and Therapy, Vol. 4, Issue. 4, p. 391.
Bergen, Phillip J. Bulman, Zackery P. Saju, Sarith Bulitta, Juergen B. Landersdorfer, Cornelia Forrest, Alan Li, Jian Nation, Roger L. and Tsuji, Brian T. 2015. Polymyxin Combinations: Pharmacokinetics and Pharmacodynamics for Rationale Use. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Vol. 35, Issue. 1, p. 34.
Chen, Zhijin Chen, Yu Fang, Yaogao Wang, Xiaotian Chen, Yanqing Qi, Qingsong Huang, Fang and Xiao, Xungang 2015. Meta-analysis of colistin for the treatment of Acinetobacter baumannii infection. Scientific Reports, Vol. 5, p. 17091.
Craven, Donald E. Hudcova, Jana and Rashid, Jawad 2015. Antibiotic therapy for ventilator-associated tracheobronchitis. Current Opinion in Pulmonary Medicine, Vol. 21, Issue. 3, p. 250.
The aim of this study was to compare the responses of colistin treatment alone vs. a combination of colistin and rifampicin in the treatment of ventilator-associated pneumonia (VAP) caused by a carbapenem-resistant A. baumannii strain. Forty-three patients were randomly assigned to one of two treatment groups. Although clinical (P = 0·654), laboratory (P = 0·645), radiological (P = 0·290) and microbiological (P = 0·597) response rates were better in the combination group, these differences were not significant. However, time to microbiological clearance (3·1 ± 0·5 days, P = 0·029) was significantly shorter in the combination group. The VAP-related mortality rates were 63·6% (14/22) and 38·1% (8/21) for the colistin and the combination groups (P = 0·171), respectively. Our results suggest that the combination of colistin with rifampicin may improve clinical and microbiological outcomes of VAP patients infected with A. baumannii.
This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
Email your librarian or administrator to recommend adding this journal to your organisation's collection.